Answers are grounded in this paper and cite their sources.
Real-world analysis compares CAR T and standard therapy outcomes in third-line treatment for follicular lymphoma, highlighting benefits.
In this real-world analysis, CAR T was associated with longer TTNT, longer TFI, and lower downstream FL-related costs compared with non-CAR T therapy, with interpretation informed by differences in follow-up time and treatment context.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.